abstract: BACKGROUND: The Paris classification (PC) of paediatric @entity1 (PIBD) categorises disease extent and therefore impacts on treatment decisions Histological (microscopic) disease extent is not incorporated and endoscopic (macroscopic) findings may underrepresent disease extent when compared to histological findings; this study compares disease extent at presentation. METHODS: Data were obtained of @entity0 below 17 years of age diagnosed with IBD from 2010-13 at University Hospital Southampton. Data are presented as percentage of @entity0 undergoing endoscopy. PC was performed alongside a modified PC by histological disease location. RESULTS: 172 @entity0 were identified (median age at diagnosis 13.5, 115 male); @entity2 ( @entity2 )- 107, @entity3 ( @entity3 )- 50, @entity1 Unclassified (IBDU)- 15; 159 had undergone upper GI endoscopy, 163 had undergone lower GI endoscopy. @entity4 was more extensive at all points for @entity2 , @entity3 and IBDU. @entity2 ; @entity5 in 49% of @entity0 compared to histological disease in 71.3%. Comparing PC; a 10% increase in L3 disease (ileocolonic), a 24% increase in L3+L4a disease (ileocolonic plus upper gastrointestinal (GI)) and a 27% increase in all upper GI involvement if histological disease extent was used. @entity3 ; the most common disease location was the rectum (endoscopic- 91.5% vs histological- 93.6%) and descending colon (endoscopic- 89.4% vs histological-95.7%). Comparing PC; a 19% increase in @entity4 (pancolitis) if histological disease extent was used. CONCLUSION: This data confirms that histological disease extent is greater than endoscopic disease extent. This should be considered when the PC is used. Further study is needed to elucidate which classification would better predict disease outcome.

title: Endoscopic Versus @entity4 extent at Presentation of Paediatric XXXX .

answer: @entity1


abstract: OBJECTIVE: The reported mortality @entity2 repair (eEVAR) compared with open repair in @entity0 with a @entity3 ( @entity3 ), as observed in observational studies, might be flawed by selection bias based on anatomical suitability for eEVAR. In the present study, we compared mortality in EVAR suitable versus non-EVAR-suitable @entity0 with a @entity1 who were all treated with conventional open repair. MATERIALS AND METHODS: In all @entity0 presenting with a suspected @entity3 , computed tomography angiography (CTA) scanning was performed. All consecutive @entity0 with a confirmed @entity3 on preoperative CTA scan and treated with open repair between April 2002 and April 2008 were included. Anatomical suitability for eEVAR was determined by two blinded independent reviewers. Outcomes evaluated were mortality (intra-operative, 30-day, and 6-month), morbidity, complications requiring re-intervention and length of hospital stay. RESULTS: A total of 107 consecutive @entity0 presented with a @entity3 and underwent preoperative CTA scanning. In 25 @entity0 , eEVAR was performed. In the 82 @entity0 who underwent open repair, CTA showed an EVAR-suitable @entity3 in 33 @entity0 (41.8%) and a non-EVAR-suitable @entity3 in 49 @entity0 . Thirty-day and 6-month mortality rate was 15/33 (45.5%; 95% confidence interval (CI) 28.1-63.7) and 18/33 (54.5%; 95% CI 36.4-71.9) in the EVAR-suitable group versus 24/49 (49.0%; 95% CI 34.4-63.7) (P=0.75) and 29/49 (59.2%; 95% CI 44.2-73.0) (P=0.68) in the non-EVAR-suitable group, respectively. CONCLUSIONS: The present study suggests that anatomical suitability for EVAR is not associated with lower early and midterm mortality in @entity0 treated with open @entity1 repair. Therefore, the reported reduction in mortality between eEVAR and open repair is unlikely due to selection bias based on anatomical AAA configuration.

title: EVAR suitability is not a predictor for early and midterm mortality after open XXXX repair.

answer: @entity1


abstract: In a large, double-blind, multicentre study, 269 @entity0 with confirmed @entity2 were randomly allocated to receive either @entity5 (200 mg twice daily; n = 137) or @entity7 (2.5 mg twice weekly; n = 132) for 6 months. The two groups were comparable in terms of the staging of @entity2 by the American Fertility Society (1979) score. After the sixth month of treatment, repeat laparoscopy was performed. Clinical assessment, haematological and biochemical investigations were carried out during the 6 months of treatment and for a further 12 months' follow-up and are compared between the two groups. A total of 15 @entity0 from the @entity7 group, including four @entity0 with @entity6 , and 17 @entity0 from the @entity5 group, including six @entity0 with @entity1 , withdrew because of adverse symptoms. An additional 22 @entity0 , including 10 from the @entity7 group and 12 from the @entity5 group withdrew because of lack of efficacy, pregnancy, elevated hepatic function tests or for reasons unrelated to the trial. Total American Fertility Society scoring showed an improvement of 73.3% in 101 @entity0 receiving @entity7 and 72.7% in 99 @entity0 receiving @entity5 . The results showed a significant reduction in the severity of dysmenorrhoea by the third month in the @entity5 group and at 6 months in both groups. There was a significant (P < 0.001) increase in weight observed in both groups during treatment. Overall, the tolerability of @entity5 and @entity7 was good; however, significantly more @entity0 with @entity7 complained of @entity6 while significantly more with @entity5 complained of leg cramps. During the 12 months of follow-up, mild, moderate or severe degrees of lower @entity3 , dysmenorrhoea and deep @entity4 all fluctuated, with no statistically significant increase in frequency in either group.

title: Updating the clinical experience in XXXX --the European perspective.

answer: @entity2


abstract: PURPOSE: To compare the clinical outcomes between medial soft-tissue surgery and medial patellofemoral ligament (MPFL) reconstruction for recurrent @entity1 without any evident predisposing factors. METHODS: A literature search was performed on the established medical databases MEDLINE, EMBASE, and the Cochrane register. The inclusion criteria were as follows: English-language papers for recurrent @entity1 without any evident predisposing factors, clinical trial(s) with clear description of surgical technique, adult subjects, medial soft-tissue surgery or MPFL reconstruction without combined surgery, and a follow-up longer than 2 years. The methodological quality of all articles was assessed by 2 authors according to the Coleman methodology score. RESULTS: Thirteen studies (mean Coleman methodology score value, 74.1; standard deviation, 11.5) were included in the analysis. Five studies reported the outcomes of @entity0 undergoing medial soft-tissue surgery, compared with 7 studies reporting MPFL reconstruction. Overall, 109 @entity0 underwent medial soft-tissue surgery with a minimum 2-years follow-up, compared with 308 @entity0 of MPFL reconstruction. There was one direct comparative study between medial soft-tissue surgery and MPFL reconstruction. Of the @entity0 who received medial soft-tissue surgery, 0 to 9.7% experienced redislocation, compared with 0 to 10.7% of the MPFL reconstruction group. The ranges of differences in Kujala scores were 23.6 to 31.7 points in @entity0 who underwent medial soft-tissue surgery and 23.11 to 38.8 points in @entity0 who underwent MPFL reconstruction. The ranges of postoperative congruence angles were  -14.4   to 8.2   for medial soft-tissue surgery and  -7.7   to  -5.2   for MPFL reconstruction. The ranges of postoperative lateral patellofemoral angles were 7.9   to 9.4   for medial soft-tissue surgery and 5   to 5.3   for MPFL reconstruction. CONCLUSIONS: All studies on medial soft-tissue surgery and MPFL reconstruction for recurrent @entity1 without predisposing factors showed satisfactory outcomes despite the use of numerous surgical techniques, graft types, and follow-up periods. LEVEL OF EVIDENCE: Level IV, Systematic Review.

title: Medial Soft-Tissue Realignment Versus Medial Patellofemoral Ligament Reconstruction for Recurrent XXXX : Systematic Review.

answer: @entity1


abstract: Out of a series of 146 @entity0 with @entity2 (6.2%) underwent colon interposition from 1963 to 1971. All eight surviving @entity0 were seen at follow-up after a mean of 22 years. Three @entity0 were free of specific symptoms according to the criteria of DeMeester, two had moderate and three severe @entity1 . The mean time for consuming a standardized test meal was 15 minutes, compared to 8 minutes in healthy controls. @entity0 required 1-9 minutes to transport liquid @entity4 through the transplant, compared to < 10 seconds in control subjects. Histological evaluation revealed a normal architecture of the colonic and ileal epithelium in three @entity0 who underwent endoscopy. In none of these @entity0 were contractions in the colon graft related to the act of swallowing recorded on manometry. Unimpaired quality of life was indicated by the Spitzer index which scored a mean of nine out of ten points. However, on a 100point visual analogue scale @entity0 scored their global quality of life 66 and the mean Gastrointestinal Quality of Life Index was 92.2, compared to 107.6 in healthy control subjects (p < 0.05). This impairment was exclusively due to specific symptoms which scored 49.3 in @entity0 and 59 in healthy individuals (p < 0.05). Physical and social functions, emotions, and inconvenience of a medical treatment were similar to control subjects. We conclude that colon interposition for long-gap oesophageal @entity3 achieves acceptable long-term functional results. However, specific symptoms lead to a considerable impairment in quality of life.

title: Long-term functional results and quality of life after colon interposition for long-gap oesophageal XXXX .

answer: @entity3


abstract: Whisker trimming produces @entity1 of cortical responses in the barrel cortex. However, it is unclear how the developmental timing modifies the effects of whisker trimming. We investigated cortical responses in thalamocortical slices that included the @entity0 barrel cortex using @entity2 fluorescence imaging. A topological relationship was observed between the thalamic stimulated sites and cortical areas showing fluorescence changes. By adjusting the position of the thalamic stimulated sites and the cortical windows in which amplitudes of the fluorescence changes were measured, we succeeded to reduce the variability of cortical responses between slices. We then investigated the effects of whisker trimming in the thalamocortical slices. Whisker trimming from 4 weeks to 8 weeks (at 4-8 weeks) of age significantly reduced cortical responses at 8 weeks. However, whisker trimming started before 4 weeks produced only slight @entity1 or no significant effect on the thalamocortical responses. As sensory deprivation during a critical developmental period is known to prevent elimination of synapses, the presence of aberrant synapses may compensate the cortical @entity1 induced by whisker trimming started before 4 weeks. To test this possibility, whisker trimming performed at 0-6 or 0-7 weeks of age was followed by regrowth of whiskers for 1-2 weeks. Clear and significant potentiation of cortical responses was observed in these @entity0 at 8 weeks when compared with those of naive @entity0 of the same age. Overall, these data suggest that whisker trimming, producing @entity1 of thalamocortical responses, prevents elimination of aberrant synapses during a critical developmental period before 4 weeks in the @entity0 barrel cortex.

title: Timing-dependent effects of whisker trimming in thalamocortical slices including the XXXX barrel cortex.

answer: @entity0


abstract: INTRODUCTION: saturated fat restriction has been recommended for @entity4 , but the role of coconut oil (Cocos nucifera L.) extra virgin, @entity8 source in the management of lipid profile remains unclear. OBJECTIVE: to evaluate the effect of nutritional treatment associated with the consumption of extra virgin coconut oil in anthropometric parameters and lipid profile. METHODS: we conducted a longitudinal study of 116 adults of both sexes presenting CAD. @entity0 were followed in two stages: the first stage (basal-3 months), intensive nutritional treatment. In the second stage (3-6 months), the subjects were divided into two groups: diet group associated with extra virgin coconut oil consumption (GDOC) and diet group (DG). Held monthly anthropometric measurements: body mass, waist circumference (WC), neck circumference (PP), body mass index (BMI). Gauged to collected blood pressure and blood samples were fasted for 12 hours, for total @entity2 analysis and fractions apoproteins ( @entity6 ), @entity3 , glycated hemoglobin (HbA1C), insulin (I). Comparing the averages at the beginning and end of the study employing the paired Student t-independent. And set the diastolic blood pressure by BMI using ANOVA. Analyses were performed using the SPSS statistical package, being significant p < 0.05. RESULTS: the mean age of the population was 62.4    7.7 years, 63.2% male, 70% elderly, 77.6% infarcted, 52.6% with @entity5 , @entity1 and @entity7 100%. In the first stage the nutritional treatment reduced body weight, WC, BMI and PP and insulin concentrations, HbA1C, HOMA-IR and QUICK, without changing the other parameters. In the second stage of the study, it was observed that the GDOC maintained the reduction of body mass, BMI, WC, with a significant difference between groups for DC (-2.1    2,7cm; p < 0.01). In addition, there was an increase in HDL-C concentrations, @entity6 , with significant difference in GD, only for HDL-C (3.1    7.4 mg/dL; p = 0.02). CONCLUSION: it was observed that the nutritional treatment associated with extra virgin coconut oil consumption reduced the CC and increased HDL-C levels in @entity0 with CAD.

title: A COCONUT EXTRA VIRGIN OIL-RICH DIET INCREASES HDL CHOLESTEROL AND DECREASES WAIST CIRCUMFERENCE AND BODY MASS IN CORONARY ARTERY DISEASE XXXX .

answer: @entity0


abstract: OBJECTIVE: To evaluate the performance of the STEPW (size, topography, extension, penetration, wall) classification system in predicting partial or complete fibroid removal on hysteroscopic myomectomy. DESIGN: Multicenter, prospective study (Canadian Task Force classification II-2). SETTING: Four hysteroscopy centers in Brazil, China, Italy, and the United States. @entity0 (S): Four hundred forty-nine @entity0 who underwent hysteroscopic resection of 465 submucous fibroids. INTERVENTION(S): Resection of the submucous fibroids (hysteroscopic myomectomy). Fibroids were scored according to the European Society for Gynaecological Endoscopy (ESGE) and STEPW classifications. The validation of the two classifications was assessed using sensitivity and specificity of each classification, with their best cutoff point. A test of equality of the two areas under the receiver operating characteristic curves was performed for correlated samples. MAIN OUTCOME MEASURE(S): Correlation of ESGE and STEPW classifications with complete or incomplete @entity3 . RESULT(S): Removal of the @entity2 was complete in 432 (92.9%) of 465 myomectomies and incomplete in 33 (7.1%). All 320 fibroids (100%) with a score <=4 in the STEPW classification were completely removed, and 112 of 145 fibroids (77.2%) with a score>4 were removed. All 33 cases of @entity1 (100%) had a STEPW score>4. Using the ESGE classification, 85 of 86 cases (98.9%) of type 0 fibroids, 278 of 298 (93.3%) of type 1, and 69 of 81 (85.2%) of type 2 were completely resected. CONCLUSION(S): Classifying submucous fibroids using the STEPW classification permits greater correlation with @entity2 by hysteroscopic myomectomy.

title: Feasibility of a new system of classification of submucous XXXX : a multicenter study.

answer: @entity2


abstract: UNASSIGNED: We discuss issues related to cochlear implantation in @entity0 with @entity1 ( @entity1 ). We describe the varied nature of this disease category including the numerous potential causes of @entity4 . The most prevalent etiology for @entity0 with @entity1 is associated with prolonged neonatal intensive care unit (NICU) stay. We discuss the potential contribution of cochlear @entity3 to this etiology. The second part of this review describes in detail our own experience at the Hospital for Sick @entity0 in Toronto, with cochlear implantation of @entity0 diagnosed with @entity1 . We outline the detection, diagnosis, and referral routes for our @entity0 . We provide an overview of our "standard operation procedures" regarding candidacy, and discuss some of the special considerations that need to be applied to @entity0 with @entity1 . This includes decisions to implant @entity0 with better audiometric thresholds that are standard in non- @entity1 @entity0 , concerns about the possibility of spontaneous remission and the appropriate timing of implantation. Finally we review an extensive published literature in outcomes after cochlear implantation (CI) in @entity1 . This is not a systematic review but rather an exercise to distill out some important reoccurring themes and the general consensus of opinion to date. Our conclusion is that the @entity2 category @entity1 , together with its numerous co-morbidities, is far too heterogeneous to make definitive statements about prognosis with CI.

title: XXXX ( @entity1 ) and cochlear implantation.

answer: @entity1


abstract: UNASSIGNED: We discuss issues related to cochlear implantation in @entity0 with @entity1 ( @entity1 ). We describe the varied nature of this disease category including the numerous potential causes of @entity4 . The most prevalent etiology for @entity0 with @entity1 is associated with prolonged neonatal intensive care unit (NICU) stay. We discuss the potential contribution of cochlear @entity3 to this etiology. The second part of this review describes in detail our own experience at the Hospital for Sick @entity0 in Toronto, with cochlear implantation of @entity0 diagnosed with @entity1 . We outline the detection, diagnosis, and referral routes for our @entity0 . We provide an overview of our "standard operation procedures" regarding candidacy, and discuss some of the special considerations that need to be applied to @entity0 with @entity1 . This includes decisions to implant @entity0 with better audiometric thresholds that are standard in non- @entity1 @entity0 , concerns about the possibility of spontaneous remission and the appropriate timing of implantation. Finally we review an extensive published literature in outcomes after cochlear implantation (CI) in @entity1 . This is not a systematic review but rather an exercise to distill out some important reoccurring themes and the general consensus of opinion to date. Our conclusion is that the @entity2 category @entity1 , together with its numerous co-morbidities, is far too heterogeneous to make definitive statements about prognosis with CI.

title: @entity1 ( XXXX ) and cochlear implantation.

answer: @entity1


abstract: @entity1 @entity4 , caused by @entity5 , is a @entity2 that is enzootic in many parts of the USA. Although Dermacentor andersoni, a major vector of A. marginale, occurs in Canada, the Canadian @entity1 herds are currently considered free of @entity1 @entity4 . There have been two outbreaks of the disease in the province of Saskatchewan, but these have been linked to the importation of infected animals. However, the distribution of @entity1 @entity4 may alter with range expansion of the vectors. The aim of the present study was to use molecular techniques to determine if Anaplasma were present in D. andersoni at a locality near its northeastern distributional limit in Saskatchewan. Nested PCR analyses of the bacterial 16S rRNA gene were conducted on the total genomic DNA of 105 individual ticks. Single strand conformation polymorphism analysis and DNA sequencing of the 11 PCR-positive amplicons revealed the presence of three species of bacteria, none of which have been previously reported in D. andersoni. Although no ticks were infected with A. marginale, a novel genotype of A. bovis was detected in eight individuals. This discovery represents the first report of A. bovis in Canada. The potential implications of this finding with respect to @entity3 and @entity4 surveillance in Canada are discussed. The other two bacterial species detected were genetically similar to " @entity6 " and Ignatzschineria larvae, the latter of which has been associated with @entity0 disease in Europe. Further investigations are needed to determine the prevalence, reservoir hosts, and pathogenicity of the Canadian genotype of A. bovis.

title: Novel genotypes of Anaplasma bovis, " XXXX Midichloria" sp. and Ignatzschineria sp. in the Rocky Mountain wood tick, Dermacentor andersoni.

answer: @entity6


abstract: Myocardial @entity1 is an important microscopic feature of @entity3 . To determine whether @entity1 in @entity3 and essential @entity2 differ in quality or quantity, and to determine whether @entity1 affects cardiac function directly, we measured the percentage of @entity1 in @entity0 of both categories and compared the severity of @entity1 with several cardiac functions. Left and right ventricular endomyocardial biopsies were performed in 25 @entity0 with essential @entity2 and in 19 @entity0 with @entity3 . Interstitial @entity1 was classified into four different microscopic types, and the percentage of total and of each type was calculated using the point-counting method. Although the percentage of total @entity1 was similar between the two groups, the type of @entity1 was different. There was no correlation between the percentage of total @entity1 and the mean size of myocytes in either group. Although there was a significant correlation between the percentage of total @entity1 and the thickness of the interventricular septum in @entity3 , such correlation was lacking in @entity2 . There was no correlation between the percentage of total @entity1 and the ejection fraction, cardiac index, or left ventricular end-diastolic pressure in either group. We concluded that the amount of myocardial @entity1 in @entity3 is no greater than that in essential @entity2 , but the type of @entity1 is different. Furthermore, in subjects in whom the ejection fraction is normal or only slightly decreased, @entity1 does not influence global cardiac functions.

title: Quantitation of myocardial fibrosis and its relation to function in essential @entity2 and XXXX .

answer: @entity3


abstract: Myocardial @entity1 is an important microscopic feature of @entity3 . To determine whether @entity1 in @entity3 and essential @entity2 differ in quality or quantity, and to determine whether @entity1 affects cardiac function directly, we measured the percentage of @entity1 in @entity0 of both categories and compared the severity of @entity1 with several cardiac functions. Left and right ventricular endomyocardial biopsies were performed in 25 @entity0 with essential @entity2 and in 19 @entity0 with @entity3 . Interstitial @entity1 was classified into four different microscopic types, and the percentage of total and of each type was calculated using the point-counting method. Although the percentage of total @entity1 was similar between the two groups, the type of @entity1 was different. There was no correlation between the percentage of total @entity1 and the mean size of myocytes in either group. Although there was a significant correlation between the percentage of total @entity1 and the thickness of the interventricular septum in @entity3 , such correlation was lacking in @entity2 . There was no correlation between the percentage of total @entity1 and the ejection fraction, cardiac index, or left ventricular end-diastolic pressure in either group. We concluded that the amount of myocardial @entity1 in @entity3 is no greater than that in essential @entity2 , but the type of @entity1 is different. Furthermore, in subjects in whom the ejection fraction is normal or only slightly decreased, @entity1 does not influence global cardiac functions.

title: Quantitation of myocardial fibrosis and its relation to function in essential XXXX and @entity3 .

answer: @entity2


abstract: BACKGROUND _ AIMS: In decompensated @entity1 , the early innate immune response to the @entity5 ( @entity5 ) agonist, lipopolysaccharides (LPS), is characterized by a hyper-production of pro-inflammatory cytokines and hypo-production of the anti-inflammatory cytokine @entity4 . In LPS-stimulated non-cirrhotic immune cells, the constitutively active glycogen synthase kinase (GSK) 3 favors pro- vs. anti-inflammatory cytokines, by acting on gene induction. However, in these cells, @entity5 dampens its own pro-inflammatory response by inducing early (within minutes) @entity3 -mediated phosphorylation of @entity6 (one of two GSK3 isoforms) on Ser9. Phosphorylation of @entity6 (Ser9) inhibits its activity, decreases pro-inflammatory cytokines, and increases @entity4 . Thus, we investigated the role of GSK3 in LPS-induced cytokine production by peripheral blood mononuclear cells (PBMCs) or monocytes from @entity0 with advanced @entity1 and normal subjects. METHODS: Cells were pre-incubated with or without GSK3 inhibitor ( @entity8 or @entity7 ) for 1h and then stimulated with LPS. Cytokine production was assessed at mRNA and secreted proteins levels, by real-time RT-PCR at 1h and ELISA at 20 h, respectively. @entity6 phosphorylation was assessed using Western blotting. RESULTS: In cirrhotic and normal PBMCs pretreated with GSK3 inhibitors, LPS-induced production of pro-inflammatory proteins @entity2 and IL-12p40 was significantly decreased while that of @entity4 was increased. LPS-induced, @entity3 -mediated phosphorylation of @entity6 on Ser9 found in normal monocytes, was abolished in cirrhotic cells. CONCLUSIONS: GSK3 is involved in the early @entity5 -mediated pro-inflammatory response in @entity0 with decompensated @entity1 . This was associated with a defect in @entity3 -mediated @entity6 phosphorylation resulting in unrestricted 'pro-inflammatory' activity of the enzyme.

title: Glycogen synthase kinase 3 involvement in the excessive proinflammatory response to LPS in @entity0 with decompensated XXXX .

answer: @entity1


abstract: BACKGROUND _ AIMS: In decompensated @entity1 , the early innate immune response to the @entity5 ( @entity5 ) agonist, lipopolysaccharides (LPS), is characterized by a hyper-production of pro-inflammatory cytokines and hypo-production of the anti-inflammatory cytokine @entity4 . In LPS-stimulated non-cirrhotic immune cells, the constitutively active glycogen synthase kinase (GSK) 3 favors pro- vs. anti-inflammatory cytokines, by acting on gene induction. However, in these cells, @entity5 dampens its own pro-inflammatory response by inducing early (within minutes) @entity3 -mediated phosphorylation of @entity6 (one of two GSK3 isoforms) on Ser9. Phosphorylation of @entity6 (Ser9) inhibits its activity, decreases pro-inflammatory cytokines, and increases @entity4 . Thus, we investigated the role of GSK3 in LPS-induced cytokine production by peripheral blood mononuclear cells (PBMCs) or monocytes from @entity0 with advanced @entity1 and normal subjects. METHODS: Cells were pre-incubated with or without GSK3 inhibitor ( @entity8 or @entity7 ) for 1h and then stimulated with LPS. Cytokine production was assessed at mRNA and secreted proteins levels, by real-time RT-PCR at 1h and ELISA at 20 h, respectively. @entity6 phosphorylation was assessed using Western blotting. RESULTS: In cirrhotic and normal PBMCs pretreated with GSK3 inhibitors, LPS-induced production of pro-inflammatory proteins @entity2 and IL-12p40 was significantly decreased while that of @entity4 was increased. LPS-induced, @entity3 -mediated phosphorylation of @entity6 on Ser9 found in normal monocytes, was abolished in cirrhotic cells. CONCLUSIONS: GSK3 is involved in the early @entity5 -mediated pro-inflammatory response in @entity0 with decompensated @entity1 . This was associated with a defect in @entity3 -mediated @entity6 phosphorylation resulting in unrestricted 'pro-inflammatory' activity of the enzyme.

title: Glycogen synthase kinase 3 involvement in the excessive proinflammatory response to LPS in XXXX with decompensated @entity1 .

answer: @entity0


abstract: BACKGROUND: @entity4 requiring pacemaker implantation is commonly associated with @entity3 ( @entity3 ), but may not be clinically apparent until restoration of sinus rhythm with ablation or cardioversion. We sought to determine frequency, time course, and predictors for pacemaker implantation after catheter ablation, and to compare the overall rates to a matched cardioversion cohort. METHODS AND RESULTS: We conducted a retrospective analysis using a large US commercial insurance database and identified 12,158 @entity3 @entity0 who underwent catheter ablation between January 1, 2005 and December 31, 2012. Over an average of 2.4  years of follow-up, 5.6  % of the @entity0 underwent pacemaker implantation. Using the Cox proportional hazards models, we found that risk of risks of pacemaker implantation was associated with older age (50-64 and >= 65 versus <50  years), female gender, higher CHADS2 score (>= 2 and 1 versus 0), higher Charlson index (>= 2 versus 0-1), certain baseline comorbidities ( @entity5 , @entity1 , and @entity2 ), and the year of ablation. There was no significant difference in the risk of pacemaker implantation between ablation @entity0 and propensity score (PS)-matched cardioversion groups (3.5 versus. 4.1  % at 1  year and 8.8 versus 8.3  % at 5  years). CONCLUSION: Overall, pacemaker implantation occurs in about 1/28 @entity0 within 1  year of catheter ablation. The overall implantation rate decreased between 2005 and 2012. Furthermore, the risk after ablation is similar to cardioversion, suggesting that @entity0 require pacing due to a common underlying electrophysiologic substrate, rather than the ablation itself.

title: Pacemaker implantation after catheter ablation for XXXX .

answer: @entity3


abstract: OBJECTIVE: No longitudinal studies beginning in childhood have estimated the cumulative prevalence of @entity2 from childhood into young adulthood. The objective of this study was to estimate the cumulative prevalence of @entity2 by young adulthood and to assess how inclusion of not otherwise specified diagnoses affects cumulative prevalence estimates. METHOD: The prospective, population-based Great Smoky Mountains Study assessed 1,420 @entity0 up to nine times from 9 through 21 years of age from 11 counties in the southeastern United States. Common @entity2 were assessed in childhood and adolescence (ages 9 to 16 years) with the @entity0 and Adolescent Psychiatric Assessment and in young adulthood (ages 19 and 21 years) with the Young Adult Psychiatric Assessment. Cumulative prevalence estimates were derived from multiple imputed datasets. RESULTS: By 21 years of age, 61.1% of @entity0 had met criteria for a well-specified @entity2 . An additional 21.4% had met criteria for a not otherwise specified disorder only, increasing the total cumulative prevalence for any @entity1 .5%. Male subjects had higher rates of substance and @entity3 compared with female subjects; therefore, they were more likely to meet criteria for a well-specified disorder (67.8% vs 56.7%) or any disorder (89.1% vs 77.8%). @entity0 with a not otherwise specified disorder only were at increased risk for a well-specified young adult disorder compared with @entity0 with no disorder in childhood. CONCLUSIONS: Only a small percentage of young @entity0 meet criteria for a @entity1 at any given time, but most do by young adulthood. As with other medical illness, @entity2 is a nearly universal experience.

title: Cumulative prevalence of XXXX by young adulthood: a prospective cohort analysis from the Great Smoky Mountains Study.

answer: @entity2


abstract: Radiation with ultrared light (UR) and with a supposed pure UVA high pressure tube leads to increase of the skin surface temperature, which is linear during UR radiation and causes @entity1 at 42 degrees C. During UVA radiation, the skin surface temperature increases in a parabolic curve and approximates 42.3 degrees C asymptotically. There is no @entity1 . Following both UR and UVA, erythema occurs at 41.4 degrees C. UVA additionally results in immediate @entity3 dependent on the dose between 6 and 20 J/cm2. UR does not induce any @entity3 . The erythema induced by UR disappears completely within 6 hours. Corresponding to the dose, the erythema persists up to 7 days after UV radiation. Immediate and delayed @entity4 overlap. The @entity3 shows a biphasic reaction. There is a maximum immediately at the end of UV radiation, reduction between 6 and 24 hours after radiation. The course of erythema and @entity3 indicates a clinically relevant part of UVB in the emission spectrum supposed to be pure UVA. A therapeutical trial was performed in 40 @entity0 suffering from severe @entity2 . In a group of 10 @entity0 , daily UR radiation up to beginning @entity1 showed good results within 3 weeks. The therapeutic effects were even better in another group of @entity0 radiated with suberythematous doses of UVA daily for the same time. UVA radiations twice a week for 6 to 8 weeks were less effective.

title: [Effects of infrared and UVA rays on the @entity0 skin and their efficacy in the treatment of XXXX ].

answer: @entity2


abstract: Radiation with ultrared light (UR) and with a supposed pure UVA high pressure tube leads to increase of the skin surface temperature, which is linear during UR radiation and causes @entity1 at 42 degrees C. During UVA radiation, the skin surface temperature increases in a parabolic curve and approximates 42.3 degrees C asymptotically. There is no @entity1 . Following both UR and UVA, erythema occurs at 41.4 degrees C. UVA additionally results in immediate @entity3 dependent on the dose between 6 and 20 J/cm2. UR does not induce any @entity3 . The erythema induced by UR disappears completely within 6 hours. Corresponding to the dose, the erythema persists up to 7 days after UV radiation. Immediate and delayed @entity4 overlap. The @entity3 shows a biphasic reaction. There is a maximum immediately at the end of UV radiation, reduction between 6 and 24 hours after radiation. The course of erythema and @entity3 indicates a clinically relevant part of UVB in the emission spectrum supposed to be pure UVA. A therapeutical trial was performed in 40 @entity0 suffering from severe @entity2 . In a group of 10 @entity0 , daily UR radiation up to beginning @entity1 showed good results within 3 weeks. The therapeutic effects were even better in another group of @entity0 radiated with suberythematous doses of UVA daily for the same time. UVA radiations twice a week for 6 to 8 weeks were less effective.

title: [Effects of infrared and UVA rays on the XXXX skin and their efficacy in the treatment of @entity2 ].

answer: @entity0


abstract: BACKGROUND: @entity10 and @entity14 -induced @entity3 is dose-limiting and mostly presents with acute symptoms that affect the activities of daily living and overall quality of life. The objective of the present study is to assess the relief of acute @entity2 with @entity11 treatment during the chemotherapy period. @entity0 AND METHODS: In this retrospective case-control study, from January 2010 to February 2015, @entity0 who experienced treatment with @entity10 and @entity14 -induced acute @entity13 were evaluated according to the NCI-CTCAE v. 4.03 grading scale. @entity13 was evaluated using a numeric rating scale (NRS) for @entity5 intensity and experienced relief under the treatment of @entity11 and using a @entity1 symptom inventory scale (NPSI) for the style of complaints. @entity0 who were diagnosed as mildly depressed according to the HOST @entity4 and @entity6 scale and who had grade 1 to 3 sensory @entity13 based on the NCI-CTCAE v. 4.03 grading scale, and who also reported >= 4/10 on a NRS were eligible. The primary end point was the rate of more than 75  % symptomatic relief under @entity11 treatment. RESULTS: Two hundred six @entity0 were included (82  % female, median age: 52.7  years). Most @entity0 had breast, gynecologic, and @entity9 (93.4  %). Ninety-one @entity0 who received @entity11 and 115 @entity0 as the control group were assessed for @entity13 every 3  weeks. Based on the NRS, a rate of more than 75  % symptomatic relief was 53.5, 58.3, and45.2  % in @entity11 arm versus 0, 0, and 0  % in the control arm in the first, second, and third visits, respectively. Side-effects of @entity11 (n   =   7) were grade 1-2 @entity7 / @entity8 (3.2  %) and @entity12 /somnolence (3.2  %) without grade 3-4 events. CONCLUSION: @entity11 has a significant clinical activity against @entity14 - @entity10 -induced acute @entity3 .

title: Efficacy of XXXX for the relief of @entity14 and @entity10 -induced acute @entity13 : a single-center retrospective case-control study.

answer: @entity11


abstract: BACKGROUND: @entity10 and @entity14 -induced @entity3 is dose-limiting and mostly presents with acute symptoms that affect the activities of daily living and overall quality of life. The objective of the present study is to assess the relief of acute @entity2 with @entity11 treatment during the chemotherapy period. @entity0 AND METHODS: In this retrospective case-control study, from January 2010 to February 2015, @entity0 who experienced treatment with @entity10 and @entity14 -induced acute @entity13 were evaluated according to the NCI-CTCAE v. 4.03 grading scale. @entity13 was evaluated using a numeric rating scale (NRS) for @entity5 intensity and experienced relief under the treatment of @entity11 and using a @entity1 symptom inventory scale (NPSI) for the style of complaints. @entity0 who were diagnosed as mildly depressed according to the HOST @entity4 and @entity6 scale and who had grade 1 to 3 sensory @entity13 based on the NCI-CTCAE v. 4.03 grading scale, and who also reported >= 4/10 on a NRS were eligible. The primary end point was the rate of more than 75  % symptomatic relief under @entity11 treatment. RESULTS: Two hundred six @entity0 were included (82  % female, median age: 52.7  years). Most @entity0 had breast, gynecologic, and @entity9 (93.4  %). Ninety-one @entity0 who received @entity11 and 115 @entity0 as the control group were assessed for @entity13 every 3  weeks. Based on the NRS, a rate of more than 75  % symptomatic relief was 53.5, 58.3, and45.2  % in @entity11 arm versus 0, 0, and 0  % in the control arm in the first, second, and third visits, respectively. Side-effects of @entity11 (n   =   7) were grade 1-2 @entity7 / @entity8 (3.2  %) and @entity12 /somnolence (3.2  %) without grade 3-4 events. CONCLUSION: @entity11 has a significant clinical activity against @entity14 - @entity10 -induced acute @entity3 .

title: Efficacy of @entity11 for the relief of @entity14 and XXXX -induced acute @entity13 : a single-center retrospective case-control study.

answer: @entity10


abstract: BACKGROUND: @entity10 and @entity14 -induced @entity3 is dose-limiting and mostly presents with acute symptoms that affect the activities of daily living and overall quality of life. The objective of the present study is to assess the relief of acute @entity2 with @entity11 treatment during the chemotherapy period. @entity0 AND METHODS: In this retrospective case-control study, from January 2010 to February 2015, @entity0 who experienced treatment with @entity10 and @entity14 -induced acute @entity13 were evaluated according to the NCI-CTCAE v. 4.03 grading scale. @entity13 was evaluated using a numeric rating scale (NRS) for @entity5 intensity and experienced relief under the treatment of @entity11 and using a @entity1 symptom inventory scale (NPSI) for the style of complaints. @entity0 who were diagnosed as mildly depressed according to the HOST @entity4 and @entity6 scale and who had grade 1 to 3 sensory @entity13 based on the NCI-CTCAE v. 4.03 grading scale, and who also reported >= 4/10 on a NRS were eligible. The primary end point was the rate of more than 75  % symptomatic relief under @entity11 treatment. RESULTS: Two hundred six @entity0 were included (82  % female, median age: 52.7  years). Most @entity0 had breast, gynecologic, and @entity9 (93.4  %). Ninety-one @entity0 who received @entity11 and 115 @entity0 as the control group were assessed for @entity13 every 3  weeks. Based on the NRS, a rate of more than 75  % symptomatic relief was 53.5, 58.3, and45.2  % in @entity11 arm versus 0, 0, and 0  % in the control arm in the first, second, and third visits, respectively. Side-effects of @entity11 (n   =   7) were grade 1-2 @entity7 / @entity8 (3.2  %) and @entity12 /somnolence (3.2  %) without grade 3-4 events. CONCLUSION: @entity11 has a significant clinical activity against @entity14 - @entity10 -induced acute @entity3 .

title: Efficacy of @entity11 for the relief of @entity14 and @entity10 -induced acute XXXX : a single-center retrospective case-control study.

answer: @entity13


abstract: BACKGROUND: @entity10 and @entity14 -induced @entity3 is dose-limiting and mostly presents with acute symptoms that affect the activities of daily living and overall quality of life. The objective of the present study is to assess the relief of acute @entity2 with @entity11 treatment during the chemotherapy period. @entity0 AND METHODS: In this retrospective case-control study, from January 2010 to February 2015, @entity0 who experienced treatment with @entity10 and @entity14 -induced acute @entity13 were evaluated according to the NCI-CTCAE v. 4.03 grading scale. @entity13 was evaluated using a numeric rating scale (NRS) for @entity5 intensity and experienced relief under the treatment of @entity11 and using a @entity1 symptom inventory scale (NPSI) for the style of complaints. @entity0 who were diagnosed as mildly depressed according to the HOST @entity4 and @entity6 scale and who had grade 1 to 3 sensory @entity13 based on the NCI-CTCAE v. 4.03 grading scale, and who also reported >= 4/10 on a NRS were eligible. The primary end point was the rate of more than 75  % symptomatic relief under @entity11 treatment. RESULTS: Two hundred six @entity0 were included (82  % female, median age: 52.7  years). Most @entity0 had breast, gynecologic, and @entity9 (93.4  %). Ninety-one @entity0 who received @entity11 and 115 @entity0 as the control group were assessed for @entity13 every 3  weeks. Based on the NRS, a rate of more than 75  % symptomatic relief was 53.5, 58.3, and45.2  % in @entity11 arm versus 0, 0, and 0  % in the control arm in the first, second, and third visits, respectively. Side-effects of @entity11 (n   =   7) were grade 1-2 @entity7 / @entity8 (3.2  %) and @entity12 /somnolence (3.2  %) without grade 3-4 events. CONCLUSION: @entity11 has a significant clinical activity against @entity14 - @entity10 -induced acute @entity3 .

title: Efficacy of @entity11 for the relief of XXXX and @entity10 -induced acute @entity13 : a single-center retrospective case-control study.

answer: @entity14


abstract: Physical characteristics of the @entity1 teat canal were examined for their influence on susceptibility to intramammary @entity0 . All quarters of 18 @entity1 were inoculated with 2 x 10(5) cfu @entity2 (Trial 1) and 20 @entity1 with 10(5) cfu Str. uberis (Trial 2) 3-4 mm into the teat canal every 3 d for 12 d. Incidence of @entity0 was similar for both pathogens, 30/72 (42%) in Trial 1 and 32/80 (40%) in Trial 2. Logistic regression analysis showed that probability of @entity0 by Str. agalactiae increased significantly with an increase in quarter peak flow rate (P < 0.05) whereas probability of @entity0 increased for Str. uberis with a decrease in teat canal length (P < 0.05). A significantly higher (P < 0.001) incidence of @entity0 by Str. uberis was observed in quarters that contained a low wet weight (< 1.8 mg) of removable keratin compared with those that contained > 1.8 mg keratin, but there was no correlation between weight of keratin and length of the teat canal. Infections by Str. uberis took significantly less (P < 0.05) time to show a rise in somatic cell count above 7.5 x 10(5) cells/ml than Str. agalactiae. The results provide evidence that these pathogens use different mechanisms to pass through the teat canal.

title: Physical characteristics of the XXXX teat canal and their influence on susceptibility to streptococcal infection.

answer: @entity1


abstract: UNASSIGNED: The activation of the @entity0 ( @entity1 ) signaling pathway reduces water loss from plants challenged by drought stress. The effect of drought-induced @entity1 signaling on the defense and nutrition allocation of plants is largely unknown. We postulated that these changes can affect herbivorous insects. We studied the effects of drought on different feeding stages of @entity5 in the wild-type A17 of @entity4 and @entity1 signaling pathway mutant sta-1. We examined the impact of drought on plant water status, induced @entity6 signaling via the @entity0 ( @entity1 ), @entity7 (JA), and @entity3 (SA) pathways, and on the host nutritional quality in terms of leaf free @entity2 content. During the penetration phase of aphid feeding, drought decreased epidermis/mesophyll resistance but increased mesophyll/phloem resistance of A17 but not sta-1 plants. Quantification of transcripts associated with @entity1 , JA and SA signaling indicated that the drought-induced up-regulation of @entity1 signaling decreased the SA-dependent defense but increased the JA-dependent defense in A17 plants. During the phloem-feeding phase, drought had little effect on the @entity2 concentrations and the associated aphid phloem-feeding parameters in both plant genotypes. In the xylem absorption stage, drought decreased xylem absorption time of aphids in both genotypes because of decreased water potential. Nevertheless, the activation of the @entity1 signaling pathway increased water-use efficiency of A17 plants by decreasing the stomatal aperture and transpiration rate. In contrast, the water potential of sta-1 plants (unable to close stomata) was too low to support xylem absorption activity of aphids; the aphids on sta-1 plants had the highest hemolymph osmolarity and lowest abundance under drought conditions. Taken together this study illustrates the significance of cross-talk between biotic-abiotic signaling pathways in plant-aphid interaction, and reveals the mechanisms leading to alter aphid fecundity in water stresses plants.

title: Up-regulation of XXXX signaling pathway facilitates aphid xylem absorption and osmoregulation under drought stress.

answer: @entity0


abstract: BACKGROUND: @entity8 or sinus tracts are frequently misdiagnosed and incorrectly treated, leading to unnecessary procedures and @entity0 suffering. An understanding of the draining of cutaneous sinus tracts will lead to more appropriate treatment. Most cases respond to conservative, nonsurgical root canal therapy. Our objective is to report 2 cases of cutaneous sinus tract secondary to chronic @entity2 that were recently observed at our hospital. METHODS: We present 2 cases of recurrent @entity4 that were initially misdiagnosed and treated with oral antibiotics without response. RESULTS: Clinical findings included palpable facial nodules with drainage, palpable intraoral cords, and poor dentition with @entity6 ; radiologic examination showed a @entity5 process consistent with @entity1 . Both of the cases were referred to the maxillofacial department, where the cyst and nonrestorable teeth were extracted. CONCLUSION: Because @entity0 with cutaneous facial sinus tracts of dental origin often do not have obvious dental symptoms, a possible dental etiology may be overlooked. If dental origin is suspected, the diagnosis is easily confirmed by dental examination and dental roentgenograms of the involved area. Early correct diagnosis, based on radiologic evidence of a periapical @entity2 and treatment of these lesions can help prevent unnecessary and ineffective antibiotic therapy or surgical treatment, reducing the possibility of further complications such as @entity3 and @entity7 .

title: XXXX of Odontogenic Origin: Two Case Reports.

answer: @entity1


abstract: OBJECTIVES: The concept of "cardioprotection" based on ejection fraction was tested to see whether @entity0 with @entity2 in whom medical treatment fails to be cardioprotective can be distinguished from those in whom it is safe to continue such treatment. BACKGROUND: Ejection fraction is of fundamental prognostic importance. Its modification by anti- @entity1 medication may allow assessment of cardioprotection from adverse outcome. METHODS: Exercise ejection fraction and the change in ejection fraction from rest to exercise were measured by radionuclide ventriculography with and without background medication in 102 mildly symptomatic @entity0 with @entity2 suitable for revascularization but initially treated medically. RESULTS: Over 20 months, 23 @entity0 experienced an adverse event. With medication, exercise ejection fraction increased in @entity0 with and without events. By contrast, the ejection fraction response to exercise improved significantly in the event-free group only; the group with events had a persistent decrease in ejection fraction. By Cox analysis, the ejection fraction response to exercise performed with medication made the most significant independent contribution to event-free survival. Comparison of areas under receiver operating characteristic curves suggested that this index is the most useful clinical measure of cardioprotection. CONCLUSIONS: An exercise-induced decrease in ejection fraction despite anti- @entity1 medication implies failure of cardioprotection and a greater short-term risk of adverse outcome and crossover to revascularization in @entity0 initially treated medically. Conversely, a preserved left ventricular performance confers a satisfactory prognosis while continuing with that treatment. Thus, the effect of medication on the ejection fraction response to exercise--a reasonable estimate of its cardioprotective efficacy--may influence the choice of continuing with such treatment or performing early revascularization.

title: Objective assessment of "cardioprotective" efficacy as a prognostic guide to management of mildly symptomatic revascularizable XXXX .

answer: @entity2


abstract: OBJECTIVES: This study was undertaken to examine the influence of plasma @entity5 [ @entity5 ] levels on coronary endothelial vasomotor function. BACKGROUND: Epidemiologic studies have demonstrated a direct relation between elevated plasma levels of @entity5 and increased risk of @entity2 . Well recognized coronary risk factors are known to affect endothelium-dependent vasomotion; however, the influence of @entity5 on coronary vasomotor function has not been determined. METHODS: We used quantitative coronary angiography to measure left anterior descending coronary artery diameter changes produced by intracoronary @entity4 and @entity6 in 30 @entity0 with angiographically normal coronary arteries. Plasma @entity5 levels were determined with enzyme-linked immunosorbent assay. RESULTS: Vasomotor response to @entity4 ranged from +13% to -47% in the proximal, from +23% to -53% in the middle and from +13% to -56% in the distal segment of the left anterior descending coronary artery. According to univariate linear regression analysis, @entity5 had a significant inverse correlation with vasomotor response to @entity4 : r = 0.47, p < 0.01 in the proximal; r = -0.61, p < 0.001 in the middle; and r = -0.52, p < 0.01 in the distal segment of the left anterior descending coronary artery. By multiple stepwise regression analysis, plasma @entity5 was the significant predictor of vasomotion in response to @entity4 in all tested segments (p < 0.01). CONCLUSIONS: Elevated @entity5 levels were associated with impairment of endothelium-dependent vasodilation even when @entity3 were not recognizable by angiography. This finding suggests that elevated plasma levels of @entity5 cause @entity1 and may contribute in part to later development of @entity3 , as shown in epidemiologic studies.

title: Influence of plasma lipoprotein (a) levels on coronary vasomotor response to XXXX .

answer: @entity4


abstract: OBJECTIVES: This study reviews the clinical outcome of a series of @entity0 with @entity8 before and after immunosuppressive therapy. BACKGROUND: Despite anti-inflammatory treatment, some @entity0 with acute @entity8 experience repeated relapses of the disease. The use of @entity4 for the treatment of @entity8 remains controversial. METHODS: Twelve @entity0 (4 @entity0 , 8 @entity0 ; mean [+/- SD] age 35.9 +/- 17.2 years, range 15 to 65) with @entity8 unrelated to any @entity5 were selected. All 12 @entity0 previously received ineffective short-term courses of low dose @entity4 and had a total of 39 relapses during a mean follow-up period of 14.2 months (range 4 to 50). A 3-month course of treatment with @entity3 , at an immunosuppressive dosage, was started (1 to 1.5 mg/kg body weight per day for 4 weeks, then gradually withdrawn). When @entity3 reduction was undertaken, all @entity0 started a 5-month course of treatment with @entity1 (1.6 g/day until @entity2 suspension, then reduced to 0.8 g/day). RESULTS: During a mean follow-up period of 41.6 months (range 7 to 104), immunosuppressive treatment with high dose @entity3 resulted in stable remission in all except one @entity0 , who experienced one relapse. In this @entity0 , the addition of @entity6 to @entity3 induced a persistent remission, which remained after 1-year follow-up. During treatment, three @entity0 had severe @entity2 -related adverse effects that in two @entity0 required replacement of @entity3 with @entity6 and @entity7 , respectively. This variation in the immunosuppressive regimen did not modify the favorable clinical outcome. CONCLUSIONS: The dose and duration of @entity2 treatment are critical factors in preventing @entity8 . High dose @entity3 with @entity1 should be considered in the treatment of @entity8 resistant to anti-inflammatory therapy. @entity7 or @entity6 should be reserved for @entity0 who do not respond to high dose @entity3 or who experience severe complications related to @entity2 therapy.

title: Immunosuppressive therapy prevents XXXX .

answer: @entity8


abstract: OBJECTIVES: The aim of this study was to evaluate @entity0 with @entity4 to 1) determine the relation between flow reserve measured by @entity8 -13 (N-13) @entity9 kinetic modeling and @entity6 severity assessed by quantitative angiography, and 2) examine whether flow reserve is impaired in regions supplied by vessels without significant @entity1 . BACKGROUND: With the advent of new therapeutic approaches for @entity3 , an accurate noninvasive approach for absolute quantification of flow and flow reserve is needed to evaluate functional severity and extent of @entity5 . @entity10 @entity9 kinetic modeling may permit such evaluation. METHODS: Twenty-seven subjects were classified into three groups: group 1 = 5 young volunteers: group 2 = 7 middle-aged volunteers; and group 3 = 15 @entity0 with @entity4 . Dynamic N-13 @entity9 positron emission tomographic imaging was performed at rest and during @entity7 infusion. A three-compartment model was fit to regional N-13 @entity9 kinetic data to determine myocardial flow. Group 3 @entity0 underwent quantitative coronary angiography. RESULTS: The regional blood flow results in @entity0 with @entity3 were classified into four subgroups: no significant detectable disease and mild (50% to 69.9% area @entity6 ), moderate (70% to 94.9% area @entity6 ) or severe (95% to 100% area @entity6 ) @entity3 . Flow reserve was 2.95 +/- 0.65; 2.09 +/- 0.47; 2.02 +/- 0.51; 1.3 +/- 0.32, respectively (p < or = 0.01 except mild vs. moderate). Flow reserve was correlated with percent area @entity6 (r = -0.56) and minimal lumen diameter (r = 0.75). In volunteers (groups 1 and 2), flow reserves were greater than in segments without detectable disease in group 3 @entity0 (4.10 +/- 0.71 and 3.79 +/- 0.42, respectively, vs. 2.88 +/- 0.56, p < or = 0.02). CONCLUSIONS: The functional severity of @entity3 measured by N-13 @entity9 positron emission tomography varied for a given @entity6 but was significantly related to angiographic severity. Among @entity0 with @entity3 , @entity2 without significant angiographic stenoses displayed reduced flow reserve than did regions in control subjects, indicating that vascular reactivity was more diffusely impaired in group 3 than was suggested by angiography. Noninvasive quantification of myocardial flow reserve using dynamic N-13 @entity9 positron emission tomography yields important functional data that permit definition of the extent of disease even when disease is not apparent by angiography.

title: Noninvasive quantification of regional myocardial flow reserve in @entity0 with @entity4 using XXXX -13 @entity9 positron emission tomography. Determination of extent of altered vascular reactivity.

answer: @entity8


abstract: OBJECTIVES: The aim of this study was to evaluate @entity0 with @entity4 to 1) determine the relation between flow reserve measured by @entity8 -13 (N-13) @entity9 kinetic modeling and @entity6 severity assessed by quantitative angiography, and 2) examine whether flow reserve is impaired in regions supplied by vessels without significant @entity1 . BACKGROUND: With the advent of new therapeutic approaches for @entity3 , an accurate noninvasive approach for absolute quantification of flow and flow reserve is needed to evaluate functional severity and extent of @entity5 . @entity10 @entity9 kinetic modeling may permit such evaluation. METHODS: Twenty-seven subjects were classified into three groups: group 1 = 5 young volunteers: group 2 = 7 middle-aged volunteers; and group 3 = 15 @entity0 with @entity4 . Dynamic N-13 @entity9 positron emission tomographic imaging was performed at rest and during @entity7 infusion. A three-compartment model was fit to regional N-13 @entity9 kinetic data to determine myocardial flow. Group 3 @entity0 underwent quantitative coronary angiography. RESULTS: The regional blood flow results in @entity0 with @entity3 were classified into four subgroups: no significant detectable disease and mild (50% to 69.9% area @entity6 ), moderate (70% to 94.9% area @entity6 ) or severe (95% to 100% area @entity6 ) @entity3 . Flow reserve was 2.95 +/- 0.65; 2.09 +/- 0.47; 2.02 +/- 0.51; 1.3 +/- 0.32, respectively (p < or = 0.01 except mild vs. moderate). Flow reserve was correlated with percent area @entity6 (r = -0.56) and minimal lumen diameter (r = 0.75). In volunteers (groups 1 and 2), flow reserves were greater than in segments without detectable disease in group 3 @entity0 (4.10 +/- 0.71 and 3.79 +/- 0.42, respectively, vs. 2.88 +/- 0.56, p < or = 0.02). CONCLUSIONS: The functional severity of @entity3 measured by N-13 @entity9 positron emission tomography varied for a given @entity6 but was significantly related to angiographic severity. Among @entity0 with @entity3 , @entity2 without significant angiographic stenoses displayed reduced flow reserve than did regions in control subjects, indicating that vascular reactivity was more diffusely impaired in group 3 than was suggested by angiography. Noninvasive quantification of myocardial flow reserve using dynamic N-13 @entity9 positron emission tomography yields important functional data that permit definition of the extent of disease even when disease is not apparent by angiography.

title: Noninvasive quantification of regional myocardial flow reserve in @entity0 with XXXX using @entity8 -13 @entity9 positron emission tomography. Determination of extent of altered vascular reactivity.

answer: @entity4


abstract: OBJECTIVES: The aim of this study was to evaluate @entity0 with @entity4 to 1) determine the relation between flow reserve measured by @entity8 -13 (N-13) @entity9 kinetic modeling and @entity6 severity assessed by quantitative angiography, and 2) examine whether flow reserve is impaired in regions supplied by vessels without significant @entity1 . BACKGROUND: With the advent of new therapeutic approaches for @entity3 , an accurate noninvasive approach for absolute quantification of flow and flow reserve is needed to evaluate functional severity and extent of @entity5 . @entity10 @entity9 kinetic modeling may permit such evaluation. METHODS: Twenty-seven subjects were classified into three groups: group 1 = 5 young volunteers: group 2 = 7 middle-aged volunteers; and group 3 = 15 @entity0 with @entity4 . Dynamic N-13 @entity9 positron emission tomographic imaging was performed at rest and during @entity7 infusion. A three-compartment model was fit to regional N-13 @entity9 kinetic data to determine myocardial flow. Group 3 @entity0 underwent quantitative coronary angiography. RESULTS: The regional blood flow results in @entity0 with @entity3 were classified into four subgroups: no significant detectable disease and mild (50% to 69.9% area @entity6 ), moderate (70% to 94.9% area @entity6 ) or severe (95% to 100% area @entity6 ) @entity3 . Flow reserve was 2.95 +/- 0.65; 2.09 +/- 0.47; 2.02 +/- 0.51; 1.3 +/- 0.32, respectively (p < or = 0.01 except mild vs. moderate). Flow reserve was correlated with percent area @entity6 (r = -0.56) and minimal lumen diameter (r = 0.75). In volunteers (groups 1 and 2), flow reserves were greater than in segments without detectable disease in group 3 @entity0 (4.10 +/- 0.71 and 3.79 +/- 0.42, respectively, vs. 2.88 +/- 0.56, p < or = 0.02). CONCLUSIONS: The functional severity of @entity3 measured by N-13 @entity9 positron emission tomography varied for a given @entity6 but was significantly related to angiographic severity. Among @entity0 with @entity3 , @entity2 without significant angiographic stenoses displayed reduced flow reserve than did regions in control subjects, indicating that vascular reactivity was more diffusely impaired in group 3 than was suggested by angiography. Noninvasive quantification of myocardial flow reserve using dynamic N-13 @entity9 positron emission tomography yields important functional data that permit definition of the extent of disease even when disease is not apparent by angiography.

title: Noninvasive quantification of regional myocardial flow reserve in @entity0 with @entity4 using @entity8 -13 XXXX positron emission tomography. Determination of extent of altered vascular reactivity.

answer: @entity9


abstract: OBJECTIVES: The aim of this study was to evaluate @entity0 with @entity4 to 1) determine the relation between flow reserve measured by @entity8 -13 (N-13) @entity9 kinetic modeling and @entity6 severity assessed by quantitative angiography, and 2) examine whether flow reserve is impaired in regions supplied by vessels without significant @entity1 . BACKGROUND: With the advent of new therapeutic approaches for @entity3 , an accurate noninvasive approach for absolute quantification of flow and flow reserve is needed to evaluate functional severity and extent of @entity5 . @entity10 @entity9 kinetic modeling may permit such evaluation. METHODS: Twenty-seven subjects were classified into three groups: group 1 = 5 young volunteers: group 2 = 7 middle-aged volunteers; and group 3 = 15 @entity0 with @entity4 . Dynamic N-13 @entity9 positron emission tomographic imaging was performed at rest and during @entity7 infusion. A three-compartment model was fit to regional N-13 @entity9 kinetic data to determine myocardial flow. Group 3 @entity0 underwent quantitative coronary angiography. RESULTS: The regional blood flow results in @entity0 with @entity3 were classified into four subgroups: no significant detectable disease and mild (50% to 69.9% area @entity6 ), moderate (70% to 94.9% area @entity6 ) or severe (95% to 100% area @entity6 ) @entity3 . Flow reserve was 2.95 +/- 0.65; 2.09 +/- 0.47; 2.02 +/- 0.51; 1.3 +/- 0.32, respectively (p < or = 0.01 except mild vs. moderate). Flow reserve was correlated with percent area @entity6 (r = -0.56) and minimal lumen diameter (r = 0.75). In volunteers (groups 1 and 2), flow reserves were greater than in segments without detectable disease in group 3 @entity0 (4.10 +/- 0.71 and 3.79 +/- 0.42, respectively, vs. 2.88 +/- 0.56, p < or = 0.02). CONCLUSIONS: The functional severity of @entity3 measured by N-13 @entity9 positron emission tomography varied for a given @entity6 but was significantly related to angiographic severity. Among @entity0 with @entity3 , @entity2 without significant angiographic stenoses displayed reduced flow reserve than did regions in control subjects, indicating that vascular reactivity was more diffusely impaired in group 3 than was suggested by angiography. Noninvasive quantification of myocardial flow reserve using dynamic N-13 @entity9 positron emission tomography yields important functional data that permit definition of the extent of disease even when disease is not apparent by angiography.

title: Noninvasive quantification of regional myocardial flow reserve in XXXX with @entity4 using @entity8 -13 @entity9 positron emission tomography. Determination of extent of altered vascular reactivity.

answer: @entity0


abstract: OBJECTIVES: Our aim was to study a population of @entity0 with @entity5 from the well defined geographic region of Tuscany in central Italy, a group virtually free of selective referral bias and therefore probably closely representative of the true @entity0 population with this disease. BACKGROUND: Most available information on clinical course, natural history and prognosis of @entity5 is based on data generated from tertiary referral centers and therefore constitutes a potentially biased perspective of the disease process in this complex and diverse condition. METHODS: The study group comprised 202 @entity0 aged 1 to 74 years (mean +/- SD 41 +/- 17) at initial diagnosis and followed up for 1 to 30 years (mean 10 +/- 5). RESULTS: Largely with the use of single or multiple drug therapy, the vast majority of @entity0 (n = 154 [76%]) were asymptomatic or mildly symptomatic and in stable or improved condition over the period of follow-up, whereas the remaining @entity0 (n = 48 [24%]) experienced deterioration, had substantial functional impairment or died. Of the 13 @entity0 (6%) who died of cardiovascular causes related to @entity5 , 11 had progressive @entity3 (including 6 in the end-stage phase) and only 2 died suddenly. The annual mortality rate for @entity1 was 0.6% and that due to @entity7 was only 0.1%; the cumulative survival rate was 97%, 95% and 92%, respectively, at 5, 10 and 15 years of follow-up. @entity4 proved to be a relatively common (n = 57 [28%]) and particularly unfavorable clinical feature, with @entity2 occurring in 9 of the 57 @entity0 . The cumulative survival rate after 15 years was 76% for @entity0 with @entity4 versus 97% for @entity0 with sinus rhythm. @entity6 occurred in 33 @entity0 (16%) but did not appear to be of prognostic significance. CONCLUSIONS: In an unselected regional population, @entity5 had a relatively benign prognosis inconsistent with its prior characterization as a generally progressive disorder, based primarily on the experience of selected referral institutions. Sudden unexpected @entity2 was distinctly uncommon, although a sizable proportion of @entity0 (particularly the subset prone to @entity4 ), did experience clinical deterioration.

title: XXXX in Tuscany: clinical course and outcome in an unselected regional population.

answer: @entity5


abstract: OBJECTIVES: This study was designed to determine the effect of oral @entity7 on the development of @entity6 tolerance in @entity0 with chronic @entity3 . BACKGROUND: Early development of @entity6 tolerance with either continuous administration of intravenous or topical @entity6 preparations or frequent dosing of oral @entity8 leads to significant attenuation of @entity6 -mediated hemodynamic and anti- @entity1 effects. In recent animal experiments, prevention of @entity5 -induced hemodynamic tolerance with a concomitant use of @entity7 was demonstrated. This finding may have important clinical relevance. METHODS: Twenty-eight @entity0 with @entity3 due to @entity4 were randomized to receive either a continuous infusion (24 h) of @entity5 alone (group I, 14 @entity0 ) or concomitantly with oral @entity7 (75 mg four times a day [group II, 14 @entity0 ]). The effect of @entity5 in each group was evaluated by analysis of variance for repeated measures. The power of the analysis to detect a 5.4-mm Hg (20%) change in mean pulmonary artery wedge pressure was 90%. RESULTS: Baseline hemodynamic variables as well as the initial hemodynamic response to @entity5 were comparable in both groups. Compared with the initial response to @entity5 , a significant attenuation of effect was found in group I at 24 h in mean (+/- SE) pulmonary artery pressure (27 +/- 4% vs. 10 +/- 3%, p < 0.05) and mean pulmonary artery wedge pressure (40 +/- 4% vs. 16 +/- 4%, p < 0.05). In group II, conversely, oral @entity7 prevented @entity5 -induced hemodynamic tolerance and resulted in a persistent effect on mean pulmonary artery and wedge pressures throughout the study period (31 +/- 3% vs. 27 +/- 4%, p = 0.13 and 37 +/- 4% vs. 34 +/- 6%, p = 0.40, respectively). In addition, the initial effect on blood pressure was attenuated at 24 h in group I (5 +/- 2% vs. 12 +/- 3%, p < 0.05) but not in group II (15 +/- 3% vs. 17 +/- 2%, p = 0.46). CONCLUSIONS: In @entity0 with @entity3 due to @entity4 , the concomitant use of oral @entity7 prevents early development of @entity6 tolerance and results in a persistent @entity6 -mediated hemodynamic effect on @entity2 and left ventricular filling pressures. These data may support the concurrent use of @entity7 in @entity0 with @entity3 treated with organic @entity8 .

title: Prevention of tolerance to hemodynamic effects of @entity8 with concomitant use of XXXX in @entity0 with @entity3 .

answer: @entity7


abstract: OBJECTIVES: This study was designed to determine the effect of oral @entity7 on the development of @entity6 tolerance in @entity0 with chronic @entity3 . BACKGROUND: Early development of @entity6 tolerance with either continuous administration of intravenous or topical @entity6 preparations or frequent dosing of oral @entity8 leads to significant attenuation of @entity6 -mediated hemodynamic and anti- @entity1 effects. In recent animal experiments, prevention of @entity5 -induced hemodynamic tolerance with a concomitant use of @entity7 was demonstrated. This finding may have important clinical relevance. METHODS: Twenty-eight @entity0 with @entity3 due to @entity4 were randomized to receive either a continuous infusion (24 h) of @entity5 alone (group I, 14 @entity0 ) or concomitantly with oral @entity7 (75 mg four times a day [group II, 14 @entity0 ]). The effect of @entity5 in each group was evaluated by analysis of variance for repeated measures. The power of the analysis to detect a 5.4-mm Hg (20%) change in mean pulmonary artery wedge pressure was 90%. RESULTS: Baseline hemodynamic variables as well as the initial hemodynamic response to @entity5 were comparable in both groups. Compared with the initial response to @entity5 , a significant attenuation of effect was found in group I at 24 h in mean (+/- SE) pulmonary artery pressure (27 +/- 4% vs. 10 +/- 3%, p < 0.05) and mean pulmonary artery wedge pressure (40 +/- 4% vs. 16 +/- 4%, p < 0.05). In group II, conversely, oral @entity7 prevented @entity5 -induced hemodynamic tolerance and resulted in a persistent effect on mean pulmonary artery and wedge pressures throughout the study period (31 +/- 3% vs. 27 +/- 4%, p = 0.13 and 37 +/- 4% vs. 34 +/- 6%, p = 0.40, respectively). In addition, the initial effect on blood pressure was attenuated at 24 h in group I (5 +/- 2% vs. 12 +/- 3%, p < 0.05) but not in group II (15 +/- 3% vs. 17 +/- 2%, p = 0.46). CONCLUSIONS: In @entity0 with @entity3 due to @entity4 , the concomitant use of oral @entity7 prevents early development of @entity6 tolerance and results in a persistent @entity6 -mediated hemodynamic effect on @entity2 and left ventricular filling pressures. These data may support the concurrent use of @entity7 in @entity0 with @entity3 treated with organic @entity8 .

title: Prevention of tolerance to hemodynamic effects of @entity8 with concomitant use of @entity7 in @entity0 with XXXX .

answer: @entity3


abstract: OBJECTIVES: This study was designed to determine the effect of oral @entity7 on the development of @entity6 tolerance in @entity0 with chronic @entity3 . BACKGROUND: Early development of @entity6 tolerance with either continuous administration of intravenous or topical @entity6 preparations or frequent dosing of oral @entity8 leads to significant attenuation of @entity6 -mediated hemodynamic and anti- @entity1 effects. In recent animal experiments, prevention of @entity5 -induced hemodynamic tolerance with a concomitant use of @entity7 was demonstrated. This finding may have important clinical relevance. METHODS: Twenty-eight @entity0 with @entity3 due to @entity4 were randomized to receive either a continuous infusion (24 h) of @entity5 alone (group I, 14 @entity0 ) or concomitantly with oral @entity7 (75 mg four times a day [group II, 14 @entity0 ]). The effect of @entity5 in each group was evaluated by analysis of variance for repeated measures. The power of the analysis to detect a 5.4-mm Hg (20%) change in mean pulmonary artery wedge pressure was 90%. RESULTS: Baseline hemodynamic variables as well as the initial hemodynamic response to @entity5 were comparable in both groups. Compared with the initial response to @entity5 , a significant attenuation of effect was found in group I at 24 h in mean (+/- SE) pulmonary artery pressure (27 +/- 4% vs. 10 +/- 3%, p < 0.05) and mean pulmonary artery wedge pressure (40 +/- 4% vs. 16 +/- 4%, p < 0.05). In group II, conversely, oral @entity7 prevented @entity5 -induced hemodynamic tolerance and resulted in a persistent effect on mean pulmonary artery and wedge pressures throughout the study period (31 +/- 3% vs. 27 +/- 4%, p = 0.13 and 37 +/- 4% vs. 34 +/- 6%, p = 0.40, respectively). In addition, the initial effect on blood pressure was attenuated at 24 h in group I (5 +/- 2% vs. 12 +/- 3%, p < 0.05) but not in group II (15 +/- 3% vs. 17 +/- 2%, p = 0.46). CONCLUSIONS: In @entity0 with @entity3 due to @entity4 , the concomitant use of oral @entity7 prevents early development of @entity6 tolerance and results in a persistent @entity6 -mediated hemodynamic effect on @entity2 and left ventricular filling pressures. These data may support the concurrent use of @entity7 in @entity0 with @entity3 treated with organic @entity8 .

title: Prevention of tolerance to hemodynamic effects of XXXX with concomitant use of @entity7 in @entity0 with @entity3 .

answer: @entity8


abstract: OBJECTIVES: This study was designed to determine the effect of oral @entity7 on the development of @entity6 tolerance in @entity0 with chronic @entity3 . BACKGROUND: Early development of @entity6 tolerance with either continuous administration of intravenous or topical @entity6 preparations or frequent dosing of oral @entity8 leads to significant attenuation of @entity6 -mediated hemodynamic and anti- @entity1 effects. In recent animal experiments, prevention of @entity5 -induced hemodynamic tolerance with a concomitant use of @entity7 was demonstrated. This finding may have important clinical relevance. METHODS: Twenty-eight @entity0 with @entity3 due to @entity4 were randomized to receive either a continuous infusion (24 h) of @entity5 alone (group I, 14 @entity0 ) or concomitantly with oral @entity7 (75 mg four times a day [group II, 14 @entity0 ]). The effect of @entity5 in each group was evaluated by analysis of variance for repeated measures. The power of the analysis to detect a 5.4-mm Hg (20%) change in mean pulmonary artery wedge pressure was 90%. RESULTS: Baseline hemodynamic variables as well as the initial hemodynamic response to @entity5 were comparable in both groups. Compared with the initial response to @entity5 , a significant attenuation of effect was found in group I at 24 h in mean (+/- SE) pulmonary artery pressure (27 +/- 4% vs. 10 +/- 3%, p < 0.05) and mean pulmonary artery wedge pressure (40 +/- 4% vs. 16 +/- 4%, p < 0.05). In group II, conversely, oral @entity7 prevented @entity5 -induced hemodynamic tolerance and resulted in a persistent effect on mean pulmonary artery and wedge pressures throughout the study period (31 +/- 3% vs. 27 +/- 4%, p = 0.13 and 37 +/- 4% vs. 34 +/- 6%, p = 0.40, respectively). In addition, the initial effect on blood pressure was attenuated at 24 h in group I (5 +/- 2% vs. 12 +/- 3%, p < 0.05) but not in group II (15 +/- 3% vs. 17 +/- 2%, p = 0.46). CONCLUSIONS: In @entity0 with @entity3 due to @entity4 , the concomitant use of oral @entity7 prevents early development of @entity6 tolerance and results in a persistent @entity6 -mediated hemodynamic effect on @entity2 and left ventricular filling pressures. These data may support the concurrent use of @entity7 in @entity0 with @entity3 treated with organic @entity8 .

title: Prevention of tolerance to hemodynamic effects of @entity8 with concomitant use of @entity7 in XXXX with @entity3 .

answer: @entity0


abstract: Serial cranial computed tomographic (CT) scanning and intracranial pressure monitoring were performed on 198 @entity0 with stage II and III @entity5 . The aims of the study were to document the course of tuberculous @entity3 during medical and surgical treatment, as well as the prognostic significance of parenchymal changes in the brain as demonstrated by CT. Lumbar cerebrospinal fluid pressure was monitored continuously for a 1-hour period in all @entity0 on admission and at weekly intervals in @entity0 with communicating @entity3 for the 1st month of treatment. Cranial CT scanning was done on admission and repeated in survivors after 1 month and again after 6 months of antituberculous therapy. The raised intracranial pressure of 112 @entity0 with communicating @entity3 , as demonstrated by air-encephalography, was treated medically (with daily @entity6 and @entity4 ) for 1 month. Thirty-one @entity0 with noncommunicating @entity3 were referred for immediate ventriculoperitoneal shunting. No significant difference was found in the eventual ventricular size or clinical outcome between the two treatment groups. Lumbar cerebrospinal fluid pressure changes in the @entity0 with communicating @entity3 closely followed changes in the degree of @entity3 during the course of treatment. The main cause of permanent @entity1 was @entity2 , which occurred unilaterally in 21% and bilaterally in 10% of @entity0 on admission and developed in a further 22% of @entity0 during treatment. A prominent subarachnoid space, which was seen on the CT scan of 36% of @entity0 after the 1st month of treatment and which reverted to normal, probably relates to the poor nutritional state of these @entity0 on admission.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Serial CT scanning in childhood XXXX : prognostic features in 198 cases.

answer: @entity5


abstract: The specificity and sensitivity of the assay for beta-glucuronidase in cerebrospinal fluid were evaluated to determine the usefulness of this test for the detection of @entity6 . The enzyme activity was first measured in cerebrospinal fluid from 131 @entity0 with @entity2 and was then prospectively measured in cerebrospinal fluid from 30 @entity0 with cytologic results that were positive for or suggestive of @entity1 . Within the first group, elevated levels of beta-glucuronidase were found only among @entity0 with @entity1 in the central nervous system, including @entity6 . Among 26 @entity0 with @entity1 in the central nervous system, including @entity6 . Among 26 @entity0 with positive cytologic results, 13 had elevated beta-glucuronidase activities. Elevated values were more frequent among @entity0 with @entity4 (75%) and @entity5 (60%). The @entity0 with these two disorders also had the highest enzyme activities. The correlation of th beta-glucuronidase level with other cerebrospinal fluid values, including total protein, @entity3 content, and cell count, was not significant. The findings of this study indicate that measurement of beta-glucuronidase in cerebrospinal fluid can be used as an adjunctive diagnostic test for @entity6 . The results should be interpreted with caution, however, because of the possibility that the elevated enzyme levels may be due to acute or subacute @entity7 .

title: Assay for beta-glucuronidase in cerebrospinal fluid: usefulness for the detection of XXXX .

answer: @entity6


abstract: A randomized, single-blind study was designed to assess the effect of @entity5 alone and @entity5 plus @entity1 on the healing and eradication rates in @entity3 -associated @entity6 . Seventy-nine @entity0 with @entity4 and 54 @entity0 with duodenal @entity2 were randomly assigned to two treatment groups. Group 1 received @entity5 30 mg daily for 8 weeks for @entity4 or 6 weeks for duodenal @entity2 . Group 2 received the group 1 regimen plus @entity1 2 g daily for 2 weeks. Healing rates at 8 weeks for the @entity4 @entity0 were 92 and 84% in groups 1 and 2, respectively (p = not significant). Healing rates at 6 weeks for duodenal @entity2 were 96% in group 1 and 100% in group 2 (p = not significant). The eradication rates of @entity3 for @entity4 @entity0 were 21 and 54% in groups 1 and 2, respectively (p < 0.05). The @entity3 eradication rates for duodenal @entity2 @entity0 were 5 and 73% in groups 1 and 2, respectively (p < 0.001). The @entity3 eradication rates in group 2 were significantly higher than in group 1. @entity5 was effective for eradicating @entity3 in this study.

title: Clinical efficacy of @entity5 in eradication of XXXX .

answer: @entity3


abstract: A randomized, single-blind study was designed to assess the effect of @entity5 alone and @entity5 plus @entity1 on the healing and eradication rates in @entity3 -associated @entity6 . Seventy-nine @entity0 with @entity4 and 54 @entity0 with duodenal @entity2 were randomly assigned to two treatment groups. Group 1 received @entity5 30 mg daily for 8 weeks for @entity4 or 6 weeks for duodenal @entity2 . Group 2 received the group 1 regimen plus @entity1 2 g daily for 2 weeks. Healing rates at 8 weeks for the @entity4 @entity0 were 92 and 84% in groups 1 and 2, respectively (p = not significant). Healing rates at 6 weeks for duodenal @entity2 were 96% in group 1 and 100% in group 2 (p = not significant). The eradication rates of @entity3 for @entity4 @entity0 were 21 and 54% in groups 1 and 2, respectively (p < 0.05). The @entity3 eradication rates for duodenal @entity2 @entity0 were 5 and 73% in groups 1 and 2, respectively (p < 0.001). The @entity3 eradication rates in group 2 were significantly higher than in group 1. @entity5 was effective for eradicating @entity3 in this study.

title: Clinical efficacy of XXXX in eradication of @entity3 .

answer: @entity5


abstract: This report examines the relationship of dietary fat and dietary @entity3 to mortality during a 10-year surveillance of a cohort of @entity0 of Japanese descent residing in Hawaii. The consumption of dietary fat (measured in grams) is related inversely and significantly to total mortality. No significant relationships exist between grams of dietary fat and any of the specific causes of @entity5 examined. No significant relationships are found between dietary @entity7 ( @entity8 , measured in grams) or dietary @entity3 (measured in milligrams) and any of the specific causes of @entity5 examined. In contrast, percentage of calories as fat is related inversely not only to total mortality, but to @entity1 mortality and to @entity2 mortality; and it is related directly to @entity6 ( @entity6 ) mortality. Percentage of calories as SFA is related inversely to @entity1 mortality and to @entity2 mortality, and it is related directly to @entity6 mortality. Only the relationship to @entity2 mortality remains significant in multivariate analysis if calories from @entity4 are excluded from the computation. Dietary @entity3 per 1000 calories is related directly to @entity6 mortality. While these data provide support for the diet-heart hypothesis, they also suggest that @entity0 with low fat intakes have a higher total mortality rate than @entity0 with higher fat intakes. This increased risk, due to an excess risk of @entity5 from @entity2 and @entity1 , indicates that there is no overall beneficial effect from a low fat diet in this cohort.

title: The relationship of dietary fat and XXXX to mortality in 10 years: the Honolulu Heart Program.

answer: @entity3


abstract: The clinico-pathological features of four examples of a distinctive benign uterine @entity1 are presented which has previously been titled atypical @entity4 . The @entity0 were all nulliparous and premenopausal. All presented with @entity3 . No @entity1 has recurred after hysterectomy (follow-up between 10 years and 10 months). All @entity1 arose from the corpus, three were localised lower segment @entity2 , one a diffuse polypoid involvement of the endometrium. Histologically all of the @entity1 showed very similar appearances with closely packed, regular, tubular glands lined by low columnar epithelium, resembling most closely basal endometrial glands and surrounded by benign connective tissue which by simple tinctorial methods appeared to be largely smooth muscle. No heterologous components were seen. In two cases squamous metaplasia was extensive, in one microcalcification was present. The histological appearances favour a type of benign mixed @entity1 but the appearances are not typical of Mullerian @entity5 . Immunocytochemistry performed on 3 cases confirmed that the stroma was in large part smooth muscle, though much of the stroma stained only weakly with monoclonal antidesmin antibody.

title: XXXX --clinical histological and immunocytochemical findings.

answer: @entity4


abstract: A 39-year-old @entity0 with the diagnosis of @entity3 was admitted to our hospital for surgical treatment. Cerebral @entity8 and @entity13 had been repeated in her past history. She was suffered from @entity1 associated with @entity11 ( @entity11 ) and @entity12 ( @entity12 ). An operative procedure was recommended because of the progressive @entity6 due to @entity3 . For @entity1 , continuous ambulatory peritoneal dialysis (CAPD) was introduced at one month before operation. As the operative procedure, valve replacement using Carpentier-Edwards bioprosthesis (27 mm) was done rather than valve reconstruction, because @entity4 of posterior leaflet and severe @entity9 of both leaflets were recognized. During operation, uncontrollable @entity5 was not observed. However, platelet transfusion was needed. We use @entity10 and antiplatelet agents jointly as postoperative anticoagulant therapy. @entity8 episodes have not been observed 4 years postoperatively. Relationship between @entity11 with @entity12 and @entity2 has been focused. The present case was considered to be the interesting case which various devices were necessary to operative management including @entity1 , cardiopulmonary bypass, selection of prosthetic heart valve, and postoperative anticoagulant therapy for preventing @entity7 formation.

title: [Successful surgical treatment of @entity3 associated with @entity12 and XXXX ].

answer: @entity11


abstract: A 39-year-old @entity0 with the diagnosis of @entity3 was admitted to our hospital for surgical treatment. Cerebral @entity8 and @entity13 had been repeated in her past history. She was suffered from @entity1 associated with @entity11 ( @entity11 ) and @entity12 ( @entity12 ). An operative procedure was recommended because of the progressive @entity6 due to @entity3 . For @entity1 , continuous ambulatory peritoneal dialysis (CAPD) was introduced at one month before operation. As the operative procedure, valve replacement using Carpentier-Edwards bioprosthesis (27 mm) was done rather than valve reconstruction, because @entity4 of posterior leaflet and severe @entity9 of both leaflets were recognized. During operation, uncontrollable @entity5 was not observed. However, platelet transfusion was needed. We use @entity10 and antiplatelet agents jointly as postoperative anticoagulant therapy. @entity8 episodes have not been observed 4 years postoperatively. Relationship between @entity11 with @entity12 and @entity2 has been focused. The present case was considered to be the interesting case which various devices were necessary to operative management including @entity1 , cardiopulmonary bypass, selection of prosthetic heart valve, and postoperative anticoagulant therapy for preventing @entity7 formation.

title: [Successful surgical treatment of @entity3 associated with XXXX and @entity11 ].

answer: @entity12


abstract: A 39-year-old @entity0 with the diagnosis of @entity3 was admitted to our hospital for surgical treatment. Cerebral @entity8 and @entity13 had been repeated in her past history. She was suffered from @entity1 associated with @entity11 ( @entity11 ) and @entity12 ( @entity12 ). An operative procedure was recommended because of the progressive @entity6 due to @entity3 . For @entity1 , continuous ambulatory peritoneal dialysis (CAPD) was introduced at one month before operation. As the operative procedure, valve replacement using Carpentier-Edwards bioprosthesis (27 mm) was done rather than valve reconstruction, because @entity4 of posterior leaflet and severe @entity9 of both leaflets were recognized. During operation, uncontrollable @entity5 was not observed. However, platelet transfusion was needed. We use @entity10 and antiplatelet agents jointly as postoperative anticoagulant therapy. @entity8 episodes have not been observed 4 years postoperatively. Relationship between @entity11 with @entity12 and @entity2 has been focused. The present case was considered to be the interesting case which various devices were necessary to operative management including @entity1 , cardiopulmonary bypass, selection of prosthetic heart valve, and postoperative anticoagulant therapy for preventing @entity7 formation.

title: [Successful surgical treatment of XXXX associated with @entity12 and @entity11 ].

answer: @entity3


abstract: A 64-year-old @entity0 experienced high grade fever, @entity3 , and hemosputum. She was admitted to a hospital for evaluation of the infiltrate on an chest X-ray. She was diagnosed as having @entity1 by sputum cytology and transferred to our hospital for operation. The @entity2 was obscure on palpation during thoractomy, but @entity2 could not be ruled out based on analysis of frozen sections. Therefore, a right lower lobectomy and mediastinal lymph node dissection were performed. @entity8 was not suspected until thrombi were observed in the dissected pulmonary artery. Urokinase and heparin were intravenously administered soon after the operation, but the @entity0 died of @entity4 of the sixth postoperative day. Examination of the operative specimen revealed @entity4 with @entity5 and no evidence of @entity2 . Atypical cells observed in sputum cytology seemed to be derived from @entity6 in the area of @entity5 . @entity7 was observed in the periphery of the @entity5 . These findings seemed to make accurate analysis of frozen sections difficult. An increasing number of cases of @entity4 is being reported in Japan. Therefore, @entity8 with false positive cytology may be encountered more frequently in the future.

title: [ @entity8 hardly differentiated from XXXX --a case report].

answer: @entity1


abstract: A 64-year-old @entity0 experienced high grade fever, @entity3 , and hemosputum. She was admitted to a hospital for evaluation of the infiltrate on an chest X-ray. She was diagnosed as having @entity1 by sputum cytology and transferred to our hospital for operation. The @entity2 was obscure on palpation during thoractomy, but @entity2 could not be ruled out based on analysis of frozen sections. Therefore, a right lower lobectomy and mediastinal lymph node dissection were performed. @entity8 was not suspected until thrombi were observed in the dissected pulmonary artery. Urokinase and heparin were intravenously administered soon after the operation, but the @entity0 died of @entity4 of the sixth postoperative day. Examination of the operative specimen revealed @entity4 with @entity5 and no evidence of @entity2 . Atypical cells observed in sputum cytology seemed to be derived from @entity6 in the area of @entity5 . @entity7 was observed in the periphery of the @entity5 . These findings seemed to make accurate analysis of frozen sections difficult. An increasing number of cases of @entity4 is being reported in Japan. Therefore, @entity8 with false positive cytology may be encountered more frequently in the future.

title: [ XXXX hardly differentiated from @entity1 --a case report].

answer: @entity8


abstract: Inflow characteristics of left and right ventricular filling were assessed in 40 @entity0 with @entity1 and in 10 normal subjects by pulsed Doppler echocardiography. @entity0 with @entity1 were subdivided into four groups, focusing on the involvement of right ventricular and septal branches of the coronary arteries. Group I consisted of 11 @entity0 with anterior @entity2 who showed an obstructive lesion of the proximal left anterior descending branch involving the first septal perforator with a patent right coronary artery. Group II consisted of 10 @entity0 with inferior @entity2 who showed an obstructive lesion of the proximal right coronary artery involving the right ventricular branch. Group III consisted of 12 @entity0 with both anterior and inferior @entity2 who showed obstructive lesions of both the proximal left anterior descending branch and the right coronary artery involving the right ventricular branch. Group IV consisted of seven @entity0 with @entity2 who showed an obstructive lesion of the diagonal branch or branches of the circumflex coronary artery with a patent left anterior descending branch and right coronary artery. Three measurements were performed from the transmitral and transtricuspidal inflow velocity patterns to assess the left and right ventricular diastolic behaviors. These measurements were: acceleration half-time, deceleration half-time of early diastolic rapid inflow, and the ratio of the peak velocity of early diastolic rapid inflow to that of the late diastolic inflow due to the atrial contraction. Impaired diastolic filling of the left ventricle compensated by enhanced left atrial contraction was observed in @entity0 with @entity1 from groups I, II, III and IV.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Noninvasive assessment of left and right ventricular filling in XXXX with a two-dimensional Doppler echocardiographic method.

answer: @entity1


abstract: Genetic polymorphisms of seven @entity0 lymphocyte proteins, analyzed by two-dimensional electrophoresis, were evaluated in respect to their suitability for paternity testing. Current data of an enlarged family and population study for five proteins ( @entity5 , @entity4 , @entity3 , @entity7 , @entity6 ), already described for a smaller population sample of Southern Germany, are presented together with evidence for a new polymorphic protein ( @entity2 ), recently observed in our survey. These six proteins occurred in isoelectric focusing as two different variants, acidic (a) and basic (b). The genetic basis of the protein variations was ascertained (i) by the presence of homozygous and heterozygous phenotypes, (ii) by the Mendelian mode of transmission of the variants as allelic gene products within 17 families and (iii) by the demonstration of a gene-dosage dependence comparing the spot intensities in homozygous and heterozygous phenotypes. For quantitative data, laser densitometric scanning of the protein spots followed by computer-assisted quantitative evaluation of the spot intensities was performed. The allele frequencies of the polymorphic protein were calculated from the phenotype distributions within a sample of 56 unrelated individuals from Southern Germany. Gene frequencies of the common alleles ranged between 0.991 and 0.518. To discuss the suitability of the two-dimensional polymorphisms for paternity testing the theoretical exclusion probabilities were assessed for seven polymorphic proteins observed in our population sample, the six polymorphisms with two alleles described here and a further polymorphism ( @entity1 ) with six alleles. For five proteins ( @entity5 , @entity3 , @entity2 , @entity6 and @entity1 ) we found sufficiently high values for the theoretical exclusion probabilities, ranging from 10% to 34%.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Two-dimensional electrophoresis of XXXX lymphocyte proteins: two-dimensional polymorphisms and paternity testing.

answer: @entity0


abstract: The merozoite is the invasive stage of the @entity2 parasite which is released by rupture of the schizont-infected erythrocyte. A monoclonal antibody against a 140 kilodalton (kDa) merozoite surface antigen of @entity5 was used to characterize and to purify this antigen. It was shown by pulse-chase metabolic labeling of mature schizonts that the 140 kDa merozoite antigen was the processed product of a 143 kDa schizont component, and that processing occurred at the time of erythrocyte rupture. Antiserum, prepared by immunizing a @entity0 with the 143/140 kDa antigen purified by immunoaffinity chromatography with the monoclonal antibody, strongly inhibited invasion of erythrocytes in vitro; Fab fragments prepared from purified rabbit IgG were inactive at blocking invasion, suggesting that agglutination of merozoites was the mechanism of invasion inhibition. The purified 143/140 kDa antigen was used in Freund's adjuvant to immunize four @entity3 . Two of the immunized animals developed fulminating @entity1 on challenge with 10(4) schizonts, as did the three control animals. The remaining two immunized animals controlled their @entity1 and developed chronic low-grade @entity4 . The animals which were partially protected were those that had developed anti-143/140 kDa antibodies capable of blocking invasion in vitro. Parasites were isolated from the chronic stage of infection (V5 population) and were compared with the original parasite population used for challenge (P population). Inhibition of invasion, immunofluorescence, and immunoprecipitation with anti-143/140 kDa monoclonal antibody, with immune @entity0 , and with monkey sera showed that the 143/140 kDa surface antigen had been replaced by multiple cross-reacting alternate antigenic forms of the molecule in the V population. Thus, specific immune response directed against a purified merozoite surface antigen resulted in the replacement of this antigen by variant or mutant forms.

title: Immunization of monkeys with a 140 kilodalton merozoite surface protein of XXXX @entity2 : appearance of alternate forms of this protein.

answer: @entity5